CA2536432A1 - Combination therapy for glycaemic control - Google Patents

Combination therapy for glycaemic control Download PDF

Info

Publication number
CA2536432A1
CA2536432A1 CA002536432A CA2536432A CA2536432A1 CA 2536432 A1 CA2536432 A1 CA 2536432A1 CA 002536432 A CA002536432 A CA 002536432A CA 2536432 A CA2536432 A CA 2536432A CA 2536432 A1 CA2536432 A1 CA 2536432A1
Authority
CA
Canada
Prior art keywords
glutaminyl
pharmaceutically acceptable
thiazolidine
diabetes mellitus
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002536432A
Other languages
English (en)
French (fr)
Inventor
Hans-Ulrich Demuth
Konrad Glund
Matthias Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2536432A1 publication Critical patent/CA2536432A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA002536432A 2003-09-02 2004-09-02 Combination therapy for glycaemic control Abandoned CA2536432A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02
US60/499,535 2003-09-02
PCT/IB2004/003082 WO2005020983A2 (en) 2003-09-02 2004-09-02 Combination therapy for glycaemic control

Publications (1)

Publication Number Publication Date
CA2536432A1 true CA2536432A1 (en) 2005-03-10

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002536432A Abandoned CA2536432A1 (en) 2003-09-02 2004-09-02 Combination therapy for glycaemic control

Country Status (14)

Country Link
US (1) US20060287251A1 (OSRAM)
EP (1) EP1663200A2 (OSRAM)
JP (1) JP2007504213A (OSRAM)
KR (1) KR20060119927A (OSRAM)
CN (1) CN1845731A (OSRAM)
AU (1) AU2004267955A1 (OSRAM)
BR (1) BRPI0413204A (OSRAM)
CA (1) CA2536432A1 (OSRAM)
EA (1) EA200600356A1 (OSRAM)
IL (1) IL173844A0 (OSRAM)
MX (1) MXPA06002127A (OSRAM)
NO (1) NO20061085L (OSRAM)
WO (1) WO2005020983A2 (OSRAM)
ZA (1) ZA200601770B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
JP2013523620A (ja) * 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
SG11201401175SA (en) * 2011-10-28 2014-09-26 Sanofi Aventis Deutschland Treatment protocol of diabetes type 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
DE122008000018I1 (de) * 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
IL163629A0 (en) * 2002-02-28 2005-12-18 Prosidion Ltd Glutaminyl derivatives and pharmaceutical compositions containing the same
AU2003293311A1 (en) * 2002-09-18 2004-04-23 Prosidion Ltd. Secondary binding site of dipeptidyl peptidase iv (dp iv)

Also Published As

Publication number Publication date
WO2005020983A3 (en) 2005-07-28
IL173844A0 (en) 2006-07-05
KR20060119927A (ko) 2006-11-24
CN1845731A (zh) 2006-10-11
ZA200601770B (en) 2007-07-25
WO2005020983A2 (en) 2005-03-10
NO20061085L (no) 2006-05-31
JP2007504213A (ja) 2007-03-01
US20060287251A1 (en) 2006-12-21
MXPA06002127A (es) 2006-05-31
EP1663200A2 (en) 2006-06-07
EA200600356A1 (ru) 2006-08-25
BRPI0413204A (pt) 2006-10-03
AU2004267955A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
US7078397B2 (en) Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US7241756B2 (en) Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
ES2390231T3 (es) Agentes farmacéuticos concomitantes y su uso
US7935723B2 (en) Use of organic compounds
Ahrén et al. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism
KR20090038908A (ko) 대사 장애의 조합 치료
KR20120016051A (ko) 제약 조성물
JP2012092136A (ja) 哺乳動物の血糖値低下のためのジペプチジルペプチダーゼｉｖエフェクターの使用
WO2007149797A2 (en) Use of organic compounds
JP2013540801A (ja) 代謝異常の治療のための組合せ医薬
CA2536432A1 (en) Combination therapy for glycaemic control
SK287823B6 (sk) Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2- methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-2,4-dione and sub-maximal amount of glimepiride and use thereof
Del Prato Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes
JP4914714B2 (ja) 脂質代謝異常の予防または治療用医薬組成物
KR101626653B1 (ko) Ｄｐｐ-ｉｖ 저해제를 함유하는 신장 질환 예방 또는 치료용 조성물
HK1165292A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FZDE Discontinued